WHO says 70 coronavirus vaccines in the works, with 3 leading candidates

WHO says 70 coronavirus vaccines in the works, with 3 leading candidates thumbnail
There are 70 coronavirus vaccines in progress globally, with three applicants already being examined in human trials, in step with the World Health Organization, as drugmakers race to find a cure for the deadly pathogen. The furthest along in the clinical process is an experimental vaccine developed with the aid of Hong Kong-listed CanSino Biologics Inc. And the Beijing Institute of Biotechnology, that’s in segment 2. The other two being tested in people are remedies developed separately by means of U.S. Drugmakers Moderna Inc. And Inovio Pharmaceuticals Inc., in keeping…

There are 70 coronavirus vaccines in progress globally, with three applicants already being examined in human trials, in step with the World Health Organization, as drugmakers race to find a cure for the deadly pathogen.

The furthest along in the clinical process is an experimental vaccine developed with the aid of Hong Kong-listed CanSino Biologics Inc. And the Beijing Institute of Biotechnology, that’s in segment 2. The other two being tested in people are remedies developed separately by means of U.S. Drugmakers Moderna Inc. And Inovio Pharmaceuticals Inc., in keeping with a WHO document.

Progress is going on an unprecedented pace in developing vaccines because the infectious pathogen seems unlikely to be stamped out via containment measures alone. The drug industry is hoping to compress the time it takes to get a vaccine to market usually about 10 to 15 years — to within the next year.

Drugmakers large and small have jumped in to try and expand a vaccine, which would be the most effective way to comprise the virus. Pharmaceutical giants like Pfizer Inc. And Sanofi have vaccine candidates within the preclinical stages,  with the WHO document.

CanSino stated final month it obtained Chinese regulatory approval to begin human trials of its vaccine. Cambridge, Massachusetts-based Moderna — which has in no way placed out a product — purchased regulatory approval to move fastly to human trials in March, skipping the years of animal trials which are the norm in growing vaccines. Inovio began its human trials a final week.

Read More